

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Xue-Ru WU

Application No.: 09/605,042

Conf. No. 6615

Filed: June 26, 2000

For: TRANSGENIC ANIMALS AS URINARY BIOEATORS...

Art Unit: 1636

Examiner: S. KAUSHAL

Washington, D.C.

Atty.'s Docket: WU=43C

Date: December 5, 2002

RECEIVED

DEC 06 2002

TECH CENTER 1600/2900

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is a [XX] Amendment [] _____
in the above-identified application.

[XX] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[XX] No additional fee is required.

[] The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		PRESENT EXTRA EQUALS
TOTAL	*	MINUS	** 20		0
INDEP.	*	MINUS	*** 3		0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					

SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE		RATE	ADDITIONAL FEE
x 9	\$		x 18	\$
x 42	\$		x 84	\$
+ 140	\$		+ 280	\$
ADDITIONAL FEE TOTAL			TOTAL	
\$			\$	

OR

OR

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

[] First - \$ 55.00
[] Second - \$ 200.00
[] Third - \$ 460.00
[] Fourth - \$ 720.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

[] First - \$ 110.00
[] Second - \$ 400.00
[] Third - \$ 920.00
[] Fourth - \$ 1440.00

Month After Time Period Set

[] Less fees (\$) already paid for ___ month(s) extension of time on _____.

[] Please charge my Deposit Account No. 02-4035 in the amount of \$_____.

[] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$_____.

[] A check in the amount of \$_____ is attached (check no.).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

By: 
ALLEN C. YUN
Registration No. 37,971

Facsimile: (202) 737-3528
Telephone: (202) 628-5197



#9
electronic
assisted
att

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: WU=43C

RECEIVED

DEC 06 2002

TECH CENTER 1600/29

In re Application of:)	Art Unit: 1633
Xue-Ru WU et al)	Examiner: KAUSHAL, S.
Appln. No.: 09/605,042)	Washington, D.C.
Filing Date: June 26, 2000)	Confirmation No. 6615
For: TRANSGENIC ANIMALS AS)	December 5, 2002
URINARY BIOREACTORS...)	

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of November 5, 2002,
primarily in the nature of a requirement for restriction, please amend
as follows:

IN THE CLAIMS

Please replace claims 1 and 29 with new amended claims 1 and
29 as follows below. A marked up version of the amended claims to show
the changes made is attached hereto.

a1
1(Once-amended). An isolated DNA molecule according to
claim 29, wherein said heterologous polypeptide contains a non-native
apical surface membrane targeting sequence.

a2
29(Once-amended). An isolated DNA molecule, comprising a
kidney-specific promoter operably linked to a heterologous DNA sequence
encoding a heterologous polypeptide, wherein said kidney-specific
promoter directs expression of said heterologous polypeptide *in vivo* in